Healthcare Economist January 20, 2025
That is according to the FDA. Nature Reviews Drug Discovery summarizes the progress to date as follows.
The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) approved 57 new therapeutic drugs (NTD) in 2024. This is slightly above the average of 53 NTDs per year for 2014–2024, and well below the all-time high of 71 approvals, in 2023.
There also has been a lot of progress on the biosimilar front as well. FDA’s 2024 report states:
CDER approved a record total of 18 biosimilars for 8 reference products in 2024, more...
Today's Sponsors
Today's Sponsor